Age-related macular degeneration (AMD) is another chronic illness that is also acknowledged. The most recent study on healthcare cost reductions, Supplement to Savings (“S2S”) from the CRN Foundation, predicted an average of more than $106 million in net savings annually when MDthe at-risk target populations of A used lutein and zeaxanthin. The CRN Foundation, carried out by Frost & Sullivan, analyzes the risk-reducing impact supplements can have on particular chronic illnesses and disorders. In August 2022, the Foundation released this investigation’s general conclusions and insights.
Age-related macular degeneration is a degenerative eye condition that worsens over time and primarily affects adults over 50. The macula, also known as the central region of the retina, which AMD characterizes, begins to deteriorate. This condition makes it difficult to see objects directly in front of you, impairs your independence and daily activities, and significantly negatively impacts your quality of life. Almost 4.2 million adults 40 and older have low vision or are blind, according to the CDC.
Lutein and zeaxanthin are xanthophylls, carotenoids that are typically found in the human diet and are well known for their antioxidant properties. According to the study, the nutrients are concentrated in the macula lutea, an essential part of the macular pigment, implicating them in protecting eyes and vision. By interacting with other pigments in the retina when light strikes them, lutein and zeaxanthin may protect the eye from oxidative damage, according to current studies.
The American Optometric Association (AOA) suggests taking 2 mg of zeaxanthin and 10mg of lutein daily. Based on American observations, this dose advised that Age-Related Eye Disease Study II (AREDS2), sponsored by the National Eye Institute, is believed to be advantageous and is also the quantity found in most currently available products.
With a focus on phytonutrients in her research, Elizabeth J. Johnson, Ph.D., an adjunct professor at Tufts University’s Friedman School of Nutrition Science & Policy, provided remarks on the potential contribution of the nutrients to reducing the effects of age-related macular degeneration. Dr. Johnson belongs to the American Society for Nutrition’s Brain and Ocular Nutrition Group, the International Carotenoid Society’s Carotenoid Research Interactive Group, and the International Carotenoid Society.
“There is no known treatment for AMD. Consequently, it is crucial to prevent or delay advancement. In order to solve this significant public health concern, it is necessary to consider the scientific findings that lutein, a dietary component frequently present in fruit and vegetables, may play a role.
From the impact, dietary supplements play in lowering risks connected with age-related macular degeneration, the CRN Foundation’s analysis findings have clear financial implications for possible long-term cost reductions for Americans.
